CDX-6210

CDX-6210 is an oral engineered enzyme replacement therapy being developed by Codexis for maple syrup urine disease. The candidate is a gastrointestinal-stable bacterial leucine decarboxylase designed to function in the gastrointestinal tract, where it degrades dietary leucine before systemic absorption and thereby aims to lower toxic circulating leucine levels that drive the neurologic complications of maple syrup urine disease. Preclinical studies described suppression of blood leucine in whey-fed maple syrup urine disease mouse models and dose-dependent plasma leucine reduction in healthy non-human primates.

Other names

engineered gastrointestinal-stable bacterial leucine decarboxylase